M&A With Big Pharma: Due Diligence Issues That Can Affect a Deal

The success of life sciences companies will depend on products and services not yet found in a companies offerings in the next decade. Much of those products will be brought to companies through the merger and acquisitions of small to mid-sized companies. This panel will discuss:

• When is the right time to get acquired?
• What is the survival rate of c-suite after an acquisition?
• Why is an acquisition better than a collaboration?
• What are the key issues in the due diligence process that can hurt the value of the deal?
• How does big pharma prepare for pricing negotiations and how can a smaller seller be prepared
• What types of steps can be taken to prepare a forecast that drives value negotiations
• How can this analysis be leverage in negotiating a collaborative or co-partner agreement

Panelists include: Ben Clark, Partner, Deloitte & Touche LLP; Jay Jesclard, Senior Manager, Deloitte Financial Advisory Services LLP; Linda Justice, Senior Manager, Deloitte Financial Advisory Services LLP; and Ronda Sroka, Partner, Deloitte Tax LLP.